Chronic human exposure to Cd results in kidney injury. It has been proposed that nephrotoxicity produced by chronic Cd exposure is via the Cd-metallothionein complex (CdMT) and not by inorganic forms of Cd. If this hypothesis is correct, then MT-null mice, which cannot form CdMT, should not develop nephrotoxicity. Control and MT-null mice were injected sc with a wide range of CdCl 2 doses, six times/week for up to 10 weeks, and their renal Cd burden, renal MT concentration, and nephrotoxicity were quantified. In control mice, renal Cd burden increased in a doseand time-dependent manner, reaching as high as 140 fig Cd/g kidney, along with 150-fold increases in renal MT concentrations, reaching 800 /ig MT/g kidney. In MT-null mice, renal Cd concentration (10 fig/g ) was much lower, and renal MT was nonexistent. The maximum tolerated dose of Cd in MT-null mice was approximately one-eighth that of controls. MT-null mice were more susceptible than controls to Cd-induced renal injury, as evidenced by increased urinary excretion of protein, glucose, y-glutamyltransferase, and A/-acetyl-/}-D-glucosaminidase, as well as by increased blood urea nitrogen levels. Kidneys of Cd-treated mice were enlarged and histopathology showed various types of lesions, including proximal tubular degeneration, apoptosis, atrophy, interstitial inflammation, and glomerular swelling. These lesions were more severe in MT-null than in control mice, mirroring the biochemical analyses. These data indicate that Cd-induced renal injury is not necessarily mediated through the CdMT complex and that MT is an important intracellular protein in protecting against chronic Cd nephrotoxicity. © IWS Soday of Toxfcotogy.
Cadmium (Cd) ranks sixth among the most important toxic chemicals, according to the Agency for Toxic Substances and Disease Registry priority list. Cd is widely used in industry for batteries, electroplating, plastic stabilizers, and pigments, as well as in agriculture as a contaminant in phosphate fertilizer. Cd is nonbiodegradable and environmental Cd levels are increasing. Cd is readily taken up by plants, and the major route of exposure for the general population is from Cd-contaminated food or smoking of Cd-contaminated tobacco. Inhalation of Cd dusts and fumes is an occupational hazard in some industries (Friberg et al, 1986; Goering et al, 1995) .
Chronic human exposure to Cd results in various maladies; the well-known Itai-itai disease is characterized by renal dysfunction, anemia, and osteomalacia combined with osteoporosis and intolerable pain (Friberg et al., 1986) . Cd-induced nephrotoxicity is the most important and the most frequently occurring ailment in humans chronically exposed to Cd (Goering et al., 1995; Goyer and Cherian, 1995) .
Cd-induced nephrotoxicity is thought to be dependent on the chemical form of the metal. A single injection of Cd-metallothionein complex (CdMT) produces kidney injury, whereas a single injection of CdCl 2 , even at a 10 times higher dose than CdMT, produces hepatotoxicity instead of nephrotoxicity (Nordberg et al, 1975; Min et al, 1986; Dorian et al, 1995; Liu et al, 1996b) . Therefore, it was hypothesized that CdCl 2 -induced renal injury is mediated by the CdMT complex, which is formed in liver, released into the circulation, and taken up by the kidney, resulting in toxicity (Dudley et al, 1985; Chan et al, 1993) . Thus, the CdMT complex, instead of CdCl 2 , has been used as a model to study Cd nephropathy for many years. If this scenario is correct, then MT-null mice, which cannot form the CdMT complex, should not develop nephrotoxicity. This hypothesis will be tested in this study.
Most of the total body burden of Cd is associated with metallothionein (MT). MT is a low-molecular weight, cysteine-rich protein (Kagi, 1993) . These cysteines bind and store Zn, but can also bind and "detoxify" Cd. It is well accepted that MT is responsible for the detoxication of Cd in many species. Treatment with nontoxic doses of Cd or Zn, which increase tissue MT levels, produces tolerance to the toxic effects of a subsequent lethal dose of Cd (Goering and Klaassen, 1983; Goering et al., 1995) . This tolerance (i.e., resistance) appears to be due to intracellular sequestration of Cd into an "inert" CdMT, thus reducing the interaction of Cd with target molecules (Goering et al., 1995) . Recent studies have shown that MT-transgenic mice are tolerant to Cd lethality and hepatotoxicity (Liu et al., 1995) , while MT-I/II null mice are sensitive to Cd lethality and hepatotoxicity (Michalska and Choo, 1993; Masters et al., 1994; Liu et al., 1996b) . Thus, one can definitively conclude that both constitutive and induced hepatic MT levels are important in protecting against acute CdCl 2 -induced lethality and hepatotoxicity (Klaassen and Liu, 1998) .
However, it is not known whether MT can provide longterm protection against Cd toxicity, as the reported protective effects of MT in animals and cell cultures have been done in short-term studies (Petering and Fowler, 1986; Cherian, 1995) . With long-term, low-level exposure to Cd, the capacity of MT in the liver to sequester Cd can be exceeded, which leads to liver damage and subsequent release of CdMT into the circulation. The CdMT is considered toxicologically "inert" when stored intracellularly; however, it becomes a potent nephrotoxicant after reaching the systemic circulation (Cherian et al., 1976; Klaassen, 1996) . There is little or no information on the role of intracellular MT in chronic Cd nephrotoxicity. Therefore, the second goal of this study is to use the MT-null mouse model to critically determine whether MT protects against chronic Cd-induced renal injury.
MATERIALS AND METHODS
Chemicals. CdCl 2 was obtained from Fisher Scientific Co. (Fair Lawn, NJ). CdCl 2 was prepared for injection by dissolving it in 0.9% NaCl.
109 CdCl 2 (5.12 mCi/mg) was obtained from New England Nuclear (Boston, MA). yV-Acetyl-P-D-glucosaminidase kits were purchased from Boehringer (Indianapolis, IN), -y-glutamyltransferase, creatinine, glucose, and blood urea nitrogen kits were obtained from Sigma Chemical Co. (St. Louis, MO). All other chemicals were of reagent grade.
Animals. Homozygous MT-I and -FI knock-out mice (MT-null mice, \29/Sv PC S background; Masters et al., 1994) were obtained from Jackson Laboratories (Bar Harbor, ME). The homozygous mutants were mated inter se to maintain the line. Mice were housed in AAALAC accredited rooms with a 12-h light/dark cycle at 70 ± 2°F. Mice were allowed free access to mouse chow (Harian Teklad 7001, Madison, WI) and tap water. Both male and female mice, aged 6 to 8 weeks, were used in the study. Genetic background-matched mice were bred as controls, with both sex and age matched to MT-null mice. In preliminary studies, homozygous MT-I and -II knock-out mice (129/Ola X C57BL/6J background; Michalska and Choo, 1993) , obtained from the Murdoch Institute, Royal Children's Hospital (Parkville, Australia), were also used, and the results were similar (data not shown).
Animals were given
109 CdCl 2 over a wide range of doses: 0.05,0.1, 0.2,0.4, 0.8, 1.6, and2.4mgCd/kg,0.0I nCi 109 Cd/kg, sc for control mice; and 0.0125, 0.025, 0.05, 0.1, 0.2,0.4, and 0.8 mg Cd/kg, 0.01 jiCi'^Cd/kg, sc for MT-null mice. Control mice were given saline (10 ml/kg, sc). Animals were dosed six times/week for up to 10 weeks.
The mice were observed daily and body weights were recorded weekly to determine the effect of Cd on the general health of the animals. Moribund animals were euthanized with CO 2 and necropsy was performed. Although tissues were collected every week, the data from three major time intervals, namely, 3 weeks (70 mice), 6 weeks (98 mice), and 10 weeks (84 mice) of Cd administration, are presented in this paper.
Urine analysis. Twenty-two hours after the last dose of Cd, mice were hydrated (50 ml/kg, po) and then placed in metabolic cages to collect urine for a 2-h period. Urine samples were analyzed for creatinine, glucose, protein, -y-glutamyltransferase, A'-acetyl-/3-D-glucosaminidase, and lactate dehydrogenase. Protein concentration in urine was determined by a dyebinding method, with bovine serum albumin as the standard (Bradford, 1976) . Urinary glucose concentration was measured by the hexokinase/ glucose-6-phosphate dehydrogenase method, creatinine concentration was determined by the Jaffe reaction, and y-glutamyl transferase was determined by the release of 5-amino-2-nitrobenzoate from the substrate y-glutamyl-3-caj-boxy-4-nitroanilide, using commercially available kits from Sigma Chemical Co. W-Acetyl-T-D-glucosaminidase was measured colonmetrically using a Boehringer reagent kit. The urinary creatinine concentration was used to normalize the other parameters.
Tissue and blood analysis. At the end of each experiment, animals were anesthetized and decapitated to collect blood and necropsy was performed. One kidney was fixed in 10% neutral formalin, and Cd content was determined by l09 Cd analysis. Kidneys were then processed by standard histopathological techniques and stained with hematoxylin and eosin for light microscopic examination. The other kidney was homogenized in 10 mM Tns-HCl, pH 7.4, and cytosols were prepared by centrifugation (20,000g for 20 min). Metallothionein concentrations in kidney cytosols were determined by the Cd/hemoglobin radioassay (Eaton and Toal, 1982) . Serum was analyzed for blood urea nitrogen and alanine aminotransferase using commercially available kits from Sigma Chemical Co.
Statistics. Data are expressed as means ± standard error. Comparisons between control and MT-null mice were performed by the Student's I test Significance was set at p < 0.05.
RESULTS
Chronic administration of CdCl 2 resulted in dose-dependent lethality and loss of body weight in both control and MT-null mice (Fig. 1) . MT-null mice could not survive the daily dose of 0.4 mg Cd/kg sc for 3 weeks (18 injections) or the daily dose of 0.2 mg Cd/kg for 6 weeks (36 injections; 40% mice died at this time). In contrast, control mice survived daily doses of 2.4 mg Cd/kg for 4 weeks or 1.6 mg Cd/kg for 6 weeks. During the 10-week exposure period, no body weight gain was observed in MT-null mice receiving 0.1 mg Cd/kg, while a dose of 0.8 mg Cd/kg was required to produce similar effect in control mice. Thus, MT null-mice were approximately eight times more susceptible than control mice to chronic Cd toxicity.
The major target organ for chronic Cd toxicity is the kidney, and it was critical to examine the renal Cd concentrations during chronic exposure to Cd. Cd accumulation in kidney was dose-dependent (Fig. 2, left) . Maximum renal Cd concentrations (>110 jig Cd/g kidney) occurred in mice receiving daily doses higher than 0.8 mg Cd/kg. In comparison, in MT-null mice receiving daily Cd at the maximum tolerated doses, the renal Cd concentration did not exceed 10 /i,g/g kidney. Renal Cd accumulation was also time-dependent. For example, at a daily dose of 0.1 mg Cd/kg, renal Cd concentrations in control mice were 16, 34, and 64 fig/g kidney after 3 , 6, and 10 weeks of Cd injection, respectively. In contrast, in MT-null mice the right panel of Fig. 2 . Renal MT was induced up to 150-fold in control mice, reaching 800 /xg MT/g kidney at 10 weeks of exposure. In contrast, renal Cd-binding protein concentrations (MT equivalents) in MT-null mice were at background levels and remained unaltered during the 10-weeks of Cd exposure.
Urinary protein and glucose are commonly used indices for proximal tubular injury. At 3 and 6 weeks of Cd exposure, MT-null mice excreted more urinary protein and glucose than controls at doses of 0.1 mg Cd/kg and higher (Fig. 3) . It is interesting to note that after 10 weeks of multiple injections of CdCl 2 (60X), urinary protein and glucose excretion do not appear to be sensitive indices for evaluating nephrotoxicity, as they were not higher than the levels observed at 3 and 6 weeks of Cd exposure.
Urinary excretion of -y-glutamyltransferase and /V-acetyl-/3-D-glucosaminidase, two enzymes whose urinary excretion is associated with proximal tubular cell damage, were also examined (Fig. 4) . In general, increases in these two enzymes paralleled chronic CdCl 2 -induced renal morphological changes. MT-null mice excreted more of these enzymes into the urine than did control mice throughout the 10-week period of Cd exposure.
Chronic administration of CdCl 2 enlarged the kidneys in a time-and dose-dependent manner, with up to 50% increase in kidney/body weight ratios in both control and MT-null mice (Fig. 5, left) . MT-null mice had significantly higher kidney/ body weight ratios than controls at all comparable doses. Blood urea nitrogen (BUN) concentrations were also elevated dosedependently by repeated CdCl 2 administration in both control and MT-null mice (Fig. 5, right -t. FIG. 6 . Representative photomicrographs of a control mouse kidney (A) and a MT-null mouse kidney (B) following chronic exposure to CdCl 2 (0.1 mg Cd/kg, sc) for 10 weeks. Tubular degeneration, apoptosis (arrow) and glomerular swelling were more pronounced in MT-null than in control mice induced nephrotoxicity is histopathology. Chronic Cd exposure produced damage to the entire kidney, including tubular degeneration, tubular cell apoptosis, interstitial inflammation, and glomerular cell proliferation and swelling (Groten et al, 1994; Hiratsuka et al, 1996; Liu et al, 1998a) . These pathological lesions progressed with time, with more lesions being observed after 10 weeks of exposure. At the dose of 0.1 mg Cd/kg, MT-null mice (Fig. 6B) were more susceptible than control mice (Fig. 6A) to chronic Cd-induced renal lesions, including tubular degeneration, vacuolation, and tubular cell apoptosis. The glomeruli of the MT-null mice were more markedly swollen as compared to control mice.
DISCUSSION
The present study has demonstrated that chronic CdCl 2 produced renal injury in MT-null mice. We originally hypothesized that MT-null mice would be resistant to Cd nephrotoxicity, because these mice cannot synthesize the CdMT complex in response to Cd exposure. Contrary to our expectation, MT-null mice were more susceptible than control mice to chronic Cd-induced renal injury. This is the first study to clearly indicate that Cd-induced renal injury is not mediated via the CdMT complex. The possibility that Cd may bind to other low-molecular-weight proteins or thiols (such as glutathione and cysteine) for its delivery to the proximal tubular cells requires further investigation.
Cd ion has been shown to be directly toxic to renal cells, producing effects such as inhibition of Na + -glucose cotransport in renal cortical cells (Blumenthal et al, 1990) , disruption of intracellular junctions and actin filaments in LLC-PK1 cells (Prozialeck et al, 1993) , interference with DNA and protein synthesis in mesangial cells (Chin and Templeton, 1992) , and increases in LDH leakage from primary cultures of renal tubules (Groten et al., 1994) . In hamsters, inorganic Cd salts also produce acute renal injury (Rhem and Waalkes, 1990 ). These observations further support the finding that Cd-induced toxicity to kidney cells is not necessarily mediated via the CdMT complex.
Whether induction of MT is beneficial or harmful for the kidney during chronic Cd exposure has been an issue of debate for many years. Induction of MT protects liver from acute Cd toxicity by sequestrating the metal in the cytosol, but the formed CdMT complex is a potent nephrotoxicant when it is released into the circulation (Nordberg et al., 1975; Cherian et al., 1976; Squibb et al., 1984; Maitani et al., 1988; Klaassen and Liu, 1997) . The results from our recent studies indicate that the current theory for Cd nephropathy is incomplete for several reasons including: (1) renal Cd burden does not come only from CdMT, but also from inorganic Cd salts (Dorian et al., 1995; Liu et al, 1996a) ; (2) a single injection of CdMT does not mimic chronic Cd nephropathy ; (3) chronic CdMT administration produces renal injury in a manner similar to chronic CdCl 2 administration (Groten et al., 1994; Min et al, 1996; Liu et al, 1998a) , but differs from a single injection of CdMT; and (4) intracellular MT protects against chronic CdMT-induced renal injury ), but does not play a major role in acute CdMT nephrotoxicity (Liu et al., 1996b,c) .
The present study clearly demonstrates that MT serves to protect against chronic Cd toxicity. MT-null mice were approximately eight times more susceptible to chronic Cd-induced lethality and nephrotoxicity. These results have clearly demonstrated for the first time that intracellular MT not only protects against acute Cd toxicity but also protects against chronic Cd toxicity. It should also be pointed out that these MT-null mice are also more sensitive than control mice to Cd-induced chronic hepatotoxicity , immunotoxicity (Liu et al., 1998c) , and osteotoxicities . Thus, MT is an important cellular protein in protecting Cd toxicity, either from acute or from chronic exposure.
The reason why MT-null mice have an increased susceptibility to Cd-induced nephrotoxicity is not completely understood, but could result from several factors: First, the lack of MT eliminates the major protective mechanism to sequestrate Cd from critical target organelles. It is free, non-MT-bound Cd, rather than "total Cd" that produces cell injury (Goyer et al., 1989) . Additionally, Cd-induced renal damage may result from inflammation (Weiss et al, 1994) and oxidative stress (Bagchi et al, 1997; Zaman and Shaikh, 1997) . MT has also been proposed to play an important role in protecting against oxidative stress (Sato and Bremner, 1993) , and thus deficiency in MT renders the kidney of MT-null mice more susceptible to oxidative damage, as seen in the liver (Zheng et al, 1996) .
It is also important to point out that MT-null mice were more susceptible than controls to chronic CdCl 2 -induced apoptosis, as evidenced by condensed nuclei, shrinkage of cells, and increased eosinophilia (as judged by H&E stain). Apoptosis is a controlled form of cell death that serves as a molecular point of regulation for biological processes. Because the renal apoptotic cells contain high Cd content (Tanimoto et al, 1993) , apoptosis is thought to be a mode for elimination of Cd and critically damaged cells from kidneys, thus preventing the disturbance of tissue structure and integrity of the kidney. In chronic Cd-intoxicated animals, necrosis is rare, but apoptosis is common (Hamada et al, 1991; Tanimoto et al, 1993 Habeebu et al, 1998a) . Enhanced apoptosis was reported in MT-null cells or animals exposed to oxidative stress (Kondo et al, 1997) , cisplatin (Kondo et al, 1997; Liu et al, 1998e) , and chronic CdMT , supporting the notion that lack of MT results in an increase in Cdinduced apoptosis.
Other pathological lesions observed in the kidney includes tubular degeneration, glomerular cell proliferation and swelling, interstitial nephritis, and interstitial fibrosis. These lesions were dose-and time-dependent. Although the nature and type of lesions were the same in both control and MT-null mice, it took approximately eight times more Cd to produce a similar extent of injury in control mice than in MT-null mice (0.8 vs 0.1 mg Cd/kg).
In conclusion, the present study using MT-null mice has demonstrated that the renal injury produced by repeated Cd administration is not necessarily mediated via the CdMT complex and that MT is an important intracellular protein protecting against chronic Cd nephropathy.
